Navigation Links
Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
Date:6/12/2013

FARMINGDALE, N.Y., June 12, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo – facial surgery, neurosurgery,  wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today announced today that is has received a new U.S. patent on the Company's medical device products. The patent describes a means to control the output of various powered surgical devices such that power can be applied only at times where the tool is translated forward in the operative site and not at other times. By limiting power on to only the time required, tissue heating is reduced thereby improving procedure outcome and enhancing safety along with surgeon ergonomics. This action does not require the surgeon to activate switches or other mechanical means so that the action is transparent to the user. 

To date this year, six patents have been issued to Misonix, many of which apply to the Company's ultrasonic platform in general and to its BoneScalpel™ product.

Michael A. McManus, Jr., President and CEO of Misonix stated, "Misonix continues to grow and protect its core technology through continued intellectual property development and patent submissions. We believe our unique application of Ultrasound technology is one of our great assets which will continue to create growth opportunities and value going forward."

About Misonix:Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Private Securities Litigation Reform Act of 1995With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10 K, subsequent Quarterly Reports on Form 10 Q and Current Reports on Form 8 K.  The Company disclaims any obligation to update its forward looking relationships.Misonix Contact:

 Investor Relations Contact:Richard Zaremba

 Joe Diaz, Lytham Partners631-694-9555

 602-889-9700invest@misonix.com

 mson@lythampartners.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mindray Announces Appointment of Three Members to Its Executive Team
2. Ohr Pharmaceutical Announces Approval for Listing on NASDAQ
3. IRIDEX Announces Automatic Conversion of Series A Preferred Stock to Common Stock
4. River Vision Announces Receipt of Orphan Drug Designation
5. CTI Announces Data Presentations at the 18th Congress of the European Hematology Association
6. SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
7. Affiliate Retailer of Health and Wellness Products Announces New Online Store at YouNeedIt.biz
8. W.K. Kellogg Foundation announces Mission Driven Investment in SeeChange Health
9. C&J Industries Announces Additional Expansion
10. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
11. TNI BioTech, Inc. Announces Mandatory Exchange of Common Stock Certificates CUSIP Number 872608104 for New Stock Certificates with Active CUSIP 872608203
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Jan. 24, 2017   Keneric Healthcare , ... cost effective patient care products, today announced their ... expand the reach of both companies by leveraging ... expertise. Angelini Pharma Inc ... now include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal). ...
(Date:1/24/2017)... Research and Markets has announced the addition of the ... 2025" report to their offering. ... Global Optogenetics Market is poised to grow ... reach approximately $76.24 million by 2025. Some of the ... labs using optogentic techniques for neurosciences, quick growth ultrafast laser tools ...
(Date:1/24/2017)... , January 24, 2017 For ... (NASDAQ: GENE ), Alder Biopharmaceuticals Inc. (NASDAQ: ... BDSI ), and Egalet Corp. (NASDAQ: EGLT ). ... moderately lower on Monday, January 23 rd , 2017, with ... of health care companies in the S&P 500 also were ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... Manzo Pharmaceuticals, LLC., ... a Registered Trademark by the United States Patent and Trademark Office. The ... could confuse consumers into thinking that other products are similar to the patented ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... detect, and eliminate cyber threats in real-time, today announced a strategic partnership with ... enable customers to monitor, respond and protect their critical information assets and infrastructure, ...
(Date:1/24/2017)... ... January 24, 2017 , ... Bellus Medical, a leader ... of medical experts. In his new role Dr. Dobke will provide physician oversight for ... Dobke is the Head of Plastic Surgery and Associate Professor of Surgery at UC ...
(Date:1/24/2017)... IA (PRWEB) , ... January 24, 2017 , ... The ... country, has taken great care to design a program that provides teachers with the ... and domestically. This online teaching certificate is ideal for post-baccalaureate students and HigherEducation.com is ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost water advocate and host ... Change and Your Health on Voice America, once again welcomed one of her ...
Breaking Medicine News(10 mins):